Breadcrumb: Home > Solutions > Biofilm Detection
Updated:2026-11-17
Views: Biofilm risk in pharmaceutical manufacturing concentrates in the purified water and water-for-injection systems. Once a film forms on a pipe wall, a tank bottom or a valve gasket, it keeps shedding cells into the water, so microbial limits and endotoxin results exceed specification again and again in no clear pattern. Increasing the disinfectant dose usually does not help, because the problem is not insufficient strength but a film that has never been opened. This article reviews the quality and compliance risks, what the regulations require and why conventional testing misses the problem, and sets out a three-tier testing structure in which LUYOR-339 and LUYOR-330 are used to locate contamination.
The pharmaceutical industry's concern with biofilm is rooted not in the word "cleanliness" but in water. Once a biofilm forms on a pipe wall, a tank bottom or a valve gasket in a purified water or water-for-injection system, it keeps releasing cells into the water, and microbial limits and endotoxin data exceed specification repeatedly and without a clear pattern. Raising the disinfectant dose usually does not solve this, because the problem is not insufficient disinfection strength but a film that has never been opened.
Biofilm needs water, a surface and time, and a pharmaceutical water system supplies all three. Pipe walls, tank bottoms and the liquid line, valves and clamp gaskets, the cold section of heat exchangers, low-velocity branches and blind ends, and the upstream and downstream sides of sampling valves are all typical high-risk positions.
Even where the system is held in circulation at 65 to 80 °C with flow kept in the turbulent range, biofilm formation cannot be assumed away. The cold end of a heat exchanger, stagnant sections during shutdown and dead zones that cleaning does not reach can all serve as starting points. Once the film is established, routine periodic disinfection only reduces the planktonic count; the population inside the film is released again after disinfection ends.
A failed microbial limit, endotoxin or sterility test leads directly to batch rejection or to an investigation that delays release. The greater difficulty is that such excursions come and go, and the investigation is long and ties up a great deal of staff time.
Inspectors look not only at results but at whether the risk was identified, whether monitoring data exist, and whether effective corrective action followed. A cleaning validation that lacks a biofilm perspective is easily questioned at the point of whether disinfectant efficacy is weakened by the substrate.
The EPS of a biofilm consumes the active ingredients of a disinfectant, so the concentration actually reaching the cells is below the design value. The result is a false picture: the disinfection procedure is followed as written, the records are complete, yet validation does not deliver the expected log reduction. Raising the concentration at that point usually only raises cost and corrosion risk together.
Shared lines, incomplete cleaning and surfaces that CIP does not reach can all carry contamination into the next batch. The more products share a line, the harder this risk is to control by spot sampling alone.
A few documents set this out clearly:
What these requirements have in common is the demand for evidence, and for evidence from which a trend can be read. A single passing report is far less persuasive than months of point data together with corrective action records.
The methods are not unscientific; the sampling and the time and space scales do not match:
The result is that data look satisfactory all along while the problem breaks out at one particular point in time. Closing that gap needs an on-site method that covers area, gives an immediate result and leaves image evidence.
| Tier | Method | Question answered | Time |
|---|---|---|---|
| Routine inspection | UV-A fluorescence illumination, visual reading and photography | Where the contamination is, and whether cleaning removed it | Immediate |
| Point confirmation | ATP swabs, surface microbial sampling | Residue level at that point, and whether it can be released | Seconds to days |
| Laboratory confirmation | Culture counts, species identification, qPCR | Community composition, source tracing, disinfectant susceptibility | 1 to 5 days |
Each tier has its job. Fluorescence inspection steers the limited confirmation resources to the positions that really have a problem, instead of sampling blindly along the whole line; confirmation results in turn calibrate the experience-based thresholds used in reading fluorescence. Working with only one tier means either insufficient coverage or uncontrolled cost.
The principle is that proteins and peptides in the biofilm matrix, coenzymes and porphyrin metabolites emit visible fluorescence under UV-A excitation. The working rule on site is that green indicates an active biofilm while blue indicates non-living material such as dust and fibers. For the method to hold up in a pharmaceutical setting, a few points have to be kept:
Handheld devices bring these points down to the level of practice. The LUYOR-339 handheld biofilm detection lamp, for example, runs on a battery for about 5 hours continuously and supports photography while scanning, so a clean area or a production line can be covered in one pass; the more compact LUYOR-330 is better suited to narrow spaces and to reaching valves and connections. The full model comparison is in the Biofilm detection lamps section.
Fluorescence data are only worth something once they enter the cleaning validation loop. In practice they can be connected like this:
At the point-selection stage, list historical excursions, structural dead zones and poorly cleaned areas in the point table, matched one to one with the swab sites. At the baseline stage, run a full-point inspection while the equipment is known to be clean, producing reference images. At the execution stage, inspect each batch or each shift along the route, judge green fluorescent points as not acceptable and send them to rework. At the re-check stage, inspect along the same route after corrective action, prove the cleaning was effective with before-and-after images, and file the images, points, dates and operators together.
The additional benefit is that when an auditor asks how you know the disinfection procedure is effective, what you produce is not a single passing number but a set of records in which the change over time can be seen.
No. Fluorescence inspection is an on-site screening method: it answers where the contamination is and whether it has been cleaned away, gives no colony count and cannot be used to release a batch. Statutory release still requires microbial limit, endotoxin and other tests under the pharmacopoeia and GMP. The relationship is one of guidance and confirmation: inspection directs sampling to the points that really have a problem, and the test results in turn verify whether the fluorescence reading is accurate.
Not on the fluorescence result alone. Fluorescence indicates a possible organic residue or active contamination at that point, and the deviation procedure applies: first establish whether the point is product-contact and whether it falls within cleaning coverage, then sample for microbial and endotoxin testing, and decide on release, rework or rejection in the light of the results and the product risk assessment. The fluorescence image should be filed as on-site evidence in the deviation investigation.
The pipe does not have to be dismantled. Illumination can be introduced through existing openings such as sampling valve ports, manways, sight glasses and flange joints, checking low points, blind ends, welds and reducers first. For fully closed sections with no opening, inspection ports should be provided at the design stage, or an endoscope combined with fluorescence used; this is also why inspectability belongs in piping design for new projects.
Re-validation is advisable. Disinfectants differ widely in their ability to penetrate EPS and to kill attached organisms, and a disinfectant that passes a planktonic laboratory test may not remove an established film. Evaluate biofilm efficacy by a method such as ASTM E2799 or E2871, then confirm the actual cleaning result with on-site fluorescence inspection; only when the two agree is the change validated.
Yes, but the method has to be controlled. Equipment entering the area goes through the gowning and material transfer procedures and is wiped down with disinfectant; inspection is carried out with the line stopped, with no product exposed and no personnel working, to avoid raising dust and exposing people to UV. Operators must wear UV safety goggles and cover the skin. UV illumination cannot replace disinfection itself; here it is only a means of observation.
Prepare four kinds of material: a point map and list showing which risk positions are covered; baseline images showing what normal looks like; a continuous trend record showing how long the practice has run and whether the frequency has been stable; and several complete cases of fluorescence found, corrected and confirmed gone on re-check. Cases are often more persuasive than numbers, because they demonstrate both detection capability and a closed corrective loop.
Further reading: What biofilm monitoring is, and how to choose among six methods; for the operating detail see Bacterial biofilm detection: five steps and what decides the reading; for model comparison see How to choose a biofilm detection lamp.
This article belongs to the Frequently asked questions section.
Other sections on the same product line include Biofilm detection lamps (UV-A excitation of biofilm autofluorescence, which makes contamination the eye cannot see visible) and Industrial test instruments (the entry point for UV inspection, rotational speed measurement, stroboscopic observation and surface inspection).
Models mentioned in this article: LUYOR-330, XEPU-1720 . Ranges, accuracy and the accessory list for each model are given on its product page.
Email: info@xinysun.com
Tel: 131-2093-6518
Address: 1525 Minqiang Road, Bldg 26, Songjiang, Shanghai
Copyright 2026 Xinysun Instrument (Shanghai) Co., Ltd. All rights reserved.
ICP:ICP-2026046447
